{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:30:21Z","timestamp":1790692221726,"version":"4.1.0"},"reference-count":120,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.critrevonc.2026.105304","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T08:17:34Z","timestamp":1774599454000},"page":"105304","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Engineering CAR-based cellular immunotherapy for hepatocellular carcinoma: Current barriers, innovative strategies, and future directions"],"prefix":"10.1016","volume":"222","author":[{"given":"Roua","family":"Alsubki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2026.105304_bib1","unstructured":"AbelZeta announces clinical data showing preliminary anti-tumor activity for C-CAR031, an armored autologous GPC3 CAR-T, in patients with advanced hepatocellular carcinoma, at ASCO Annual Meeting 2024 - AbelZeta Pharma [WWW Document], n.d. URL \u3008https:\/\/www.abelzeta.com\/abelzeta-announces-clinical-data-showing-preliminary-anti-tumor-activity-for-c-car031-an-armored-autologous-gpc3-car-t-in-patients-with-advanced-hepatocellular-carcinoma-at-asco-annual-meeting-2024\/\u3009 (accessed 3.9.26)."},{"key":"10.1016\/j.critrevonc.2026.105304_bib2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3390\/ijms25052631","article-title":"Chimeric antigen receptor T cell therapy for hepatocellular carcinoma: where do we stand?","volume":"25","author":"Aggeletopoulou","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105304_bib3","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3390\/ijms25052631","article-title":"Chimeric antigen receptor T cell therapy for hepatocellular carcinoma: where do we stand?","volume":"25","author":"Aggeletopoulou","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105304_bib4","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13045-024-01625-7","article-title":"Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies","volume":"17","author":"Ai","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105304_bib5","first-page":"6299","article-title":"Investigation of folate-functionalized magnetic-gold nanoparticles based targeted drug delivery for liver: in vitro, in vivo and docking studies","volume":"10","author":"Alnasraui","year":"2024","journal-title":"ACS Publ."},{"key":"10.1016\/j.critrevonc.2026.105304_bib6","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3390\/cancers14010226","article-title":"Tumor-associated macrophages in hepatocellular carcinoma pathogenesis, prognosis and therapy","volume":"14","author":"Arvanitakis","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105304_bib7","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20230903","article-title":"CAR-T cell manufacturing: Major process parameters and next-generation strategies","volume":"221","author":"Ayala Ceja","year":"2024","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.critrevonc.2026.105304_bib8","article-title":"A recent prevalence of Hepatitis B Virus (HBV) genotypes and subtypes in Asia: a systematic review and meta-analysis","volume":"11","author":"Bello","year":"2023","journal-title":"Healthcare (Switzerland)"},{"key":"10.1016\/j.critrevonc.2026.105304_bib9","article-title":"vivo chimeric antigen receptor (CAR)-T cell therapy","author":"Bot","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.critrevonc.2026.105304_bib10","doi-asserted-by":"crossref","first-page":"4344","DOI":"10.4049\/jimmunol.1601070","article-title":"Lin28b regulates fetal regulatory T cell differentiation through modulation of TGF-beta signaling","volume":"197","author":"Bronevetsky","year":"2016","journal-title":"J. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105304_bib11","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2024.19462","article-title":"CAR T cells and T-cell therapies for cancer: a translational science review","volume":"332","author":"Brudno","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.critrevonc.2026.105304_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105266","article-title":"Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment","volume":"106","author":"Bui","year":"2024","journal-title":"EBioMedicine"},{"key":"10.1016\/j.critrevonc.2026.105304_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105266","article-title":"Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment","volume":"106","author":"Bui","year":"2024","journal-title":"EBioMedicine"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105304_bib14","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s00262-015-1692-6","article-title":"Liver myeloid-derived suppressor cells expand in response to liver metastases in mice and inhibit the anti-tumor efficacy of anti-CEA CAR-T","volume":"64","author":"Burga","year":"2015","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.critrevonc.2026.105304_bib15","article-title":"GPC3-targeted CAR-T cells secreting B7H3-targeted BiTE exhibit potent cytotoxicity activity against hepatocellular carcinoma cell in the in vitro assay","volume":"31","author":"Cao","year":"2022","journal-title":"Biochem. Biophys. Rep."},{"key":"10.1016\/j.critrevonc.2026.105304_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2024.101566","article-title":"Allogeneic \u201cOff-the-Shelf\u201d CAR T cells: challenges and advances","volume":"37","author":"Chen","year":"2024","journal-title":"Best. Pract. Res. Clin. Haematol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105304_bib17","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s12935-024-03315-3","article-title":"Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors","volume":"24","author":"Chen","year":"2024","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.critrevonc.2026.105304_bib18","article-title":"Advances in immune checkpoint inhibitors for advanced hepatocellular carcinoma","volume":"13","author":"Chen","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105304_bib19","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1172\/JCI83092","article-title":"Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition","volume":"126","author":"Cherkassky","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.critrevonc.2026.105304_bib20","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2025.2597064","article-title":"Cytokine release syndrome complicated with sepsis induced by tislelizumab in a patient with advanced hepatocellular carcinoma: a case report","volume":"21","author":"Chu","year":"2025","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.critrevonc.2026.105304_bib21","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2022-2837","article-title":"Abstract 2837: Synthetic TGFb blockade preserves effector function and maintains stemness of GPC3 CAR-T against hepatocellular carcinoma","volume":"82","author":"Chu","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105304_bib22","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2321545121","article-title":"A TME-enlightened protein-binding photodynamic nanoinhibitor for highly effective oncology treatment","volume":"121","author":"Cui","year":"2024","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.critrevonc.2026.105304_bib23","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/ijc.28953","article-title":"Osteopontin and latent-TGF \u03b2 binding-protein 2 as potential diagnostic markers for HBV-related hepatocellular carcinoma","volume":"136","author":"Da Costa","year":"2015","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105304_bib24","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s11262-021-01850-z","article-title":"Drug-resistant and immune-escape hepatitis B virus mutants, occult hepatitis B infection and coinfections in public hospital patients from Argentina","volume":"57","author":"Delfino","year":"2021","journal-title":"Virus Genes"},{"key":"10.1016\/j.critrevonc.2026.105304_bib25","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1097\/HEP.0000000000000362","article-title":"Hepatocellular carcinomas, exhibiting intratumor fibrosis, express cancer-specific extracellular matrix remodeling and WNT\/TGFB signatures, associated with poor outcome","volume":"78","author":"Desert","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.critrevonc.2026.105304_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101250","article-title":"CAR-T cell manufacturing landscape\u2014Lessons from the past decade and considerations for early clinical development","volume":"32","author":"Dias","year":"2024","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.critrevonc.2026.105304_bib27","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1111\/jgh.15395","article-title":"Effects of hypoxia-inducible factor-1\u03b1 and hypoxia-inducible factor-2\u03b1 overexpression on hepatocellular carcinoma survival: a systematic review with meta-analysis","volume":"36","author":"Ding","year":"2021","journal-title":"J. Gastroenterol. Hepatol. (Aust.)"},{"key":"10.1016\/j.critrevonc.2026.105304_bib28","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1093\/neuonc\/noaf115","article-title":"Transient mRNA CAR T cells targeting GD2 provide dose-adjusted efficacy against diffuse midline glioma and high-grade glioma models","volume":"27","author":"Foster","year":"2025","journal-title":"Neuro. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105304_bib29","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1053\/j.gastro.2007.03.102","article-title":"Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients","volume":"132","author":"Fu","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.critrevonc.2026.105304_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102175","article-title":"RUNX-3-expressing CAR T cells targeting glypican-3 in patients with heavily pretreated advanced hepatocellular carcinoma: a phase I trial","volume":"63","author":"Fu","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.critrevonc.2026.105304_bib31","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3390\/cells11030410","article-title":"Adoptive cellular therapy for multiple myeloma using CAR- and TCR-transgenic T cells: response and resistance","volume":"11","author":"F\u00fcchsl","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.critrevonc.2026.105304_bib32","doi-asserted-by":"crossref","first-page":"3752","DOI":"10.1158\/0008-5472.CAN-06-3851","article-title":"Src phosphorylates Tyr284 in TGF-\u03b2 type II receptor and regulates TGF-\u03b2 stimulation of p38 MAPK during breast cancer cell proliferation and invasion","volume":"67","author":"Galliher","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105304_bib33","doi-asserted-by":"crossref","first-page":"11","DOI":"10.46989\/001c.115793","article-title":"Outpatient CAR T-cell therapy as standard of care: current perspectives and considerations","volume":"6","author":"Gatwood","year":"2024","journal-title":"Clin. Hematol. Int."},{"key":"10.1016\/j.critrevonc.2026.105304_bib34","doi-asserted-by":"crossref","DOI":"10.1177\/10732748241251580","article-title":"Comprehensive analysis of the immunosuppressive function of regulatory T cells in human hepatocellular carcinoma tissues","volume":"31","author":"Ge","year":"2024","journal-title":"Cancer Control"},{"key":"10.1016\/j.critrevonc.2026.105304_bib35","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s00281-022-00942-8","article-title":"Harnessing the liver to induce antigen-specific immune tolerance","volume":"44","author":"Gottwick","year":"2022","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.critrevonc.2026.105304_bib36","first-page":"S175","article-title":"An armored anti-GPC3 CAR T therapy for hepatocellular carcinoma enhanced through multiple modules","volume":"27","author":"Gu","year":"2025","journal-title":"Cytotherapy"},{"key":"10.1016\/j.critrevonc.2026.105304_bib37","first-page":"3","article-title":"Hypoxia-inducible factors in hepatocellular carcinoma (Review)","volume":"43","author":"Guo","year":"2020","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.critrevonc.2026.105304_bib38","doi-asserted-by":"crossref","first-page":"391","DOI":"10.33073\/pjm-2020-044","article-title":"Hepatitis b virus: From diagnosis to treatment","volume":"69","author":"Guvenir","year":"2020","journal-title":"Pol. J. Microbiol."},{"key":"10.1016\/j.critrevonc.2026.105304_bib39","article-title":"Hepatitis B virus genotypes and antiviral drug resistance mutations in treatment-na\u00efve patients with chronic hepatitis B in Bacninh, Vietnam: a cross-sectional study","volume":"12","author":"Hoang","year":"2025","journal-title":"Ther. Adv. Infect. Dis."},{"key":"10.1016\/j.critrevonc.2026.105304_bib40","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3390\/biom12091303","article-title":"Co-stimulatory receptor signaling in CAR-T cells","volume":"12","author":"Honikel","year":"2022","journal-title":"Biomolecules"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105304_bib41","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13045-024-01639-1","article-title":"Advances in CAR-T cell therapy for hematologic and solid malignancies: latest updates from 2024 ESMO Congress","volume":"17","author":"Huang","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105304_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.matchemphys.2024.129446","article-title":"Investigation of dextran-coated magnetic nanoparticles encapsulated by medication and modified with folate for targeted drug delivery: Invitro and docking studies","volume":"321","author":"Hussein F Alnasraui","year":"2024","journal-title":"Mater. Chem. Phys."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105304_bib43","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s12032-023-02273-6","article-title":"Unraveling the multifaceted role of EpCAM in colorectal cancer: an integrated review of its function and interplay with non-coding RNAs","volume":"41","author":"Jiang","year":"2023","journal-title":"Med. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105304_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.powtec.2026.122244","article-title":"Advances in nanocarrier-based nose-to-brain drug delivery systems for neurological disorders - a comprehensive review","volume":"474","author":"Kamyab","year":"2026","journal-title":"Powder Technol."},{"key":"10.1016\/j.critrevonc.2026.105304_bib45","article-title":"Advances in green synthesis of nanoparticles for biomedical applications: antimicrobial, antiviral, and cancer therapies","volume":"33","author":"Kamyab","year":"2026","journal-title":"Mater. Today Sustain."},{"key":"10.1016\/j.critrevonc.2026.105304_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2025.126046","article-title":"Emerging nanoparticle-based strategies for advanced cancer imaging and diagnosis","volume":"683","author":"Kamyab","year":"2025","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.critrevonc.2026.105304_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2025.126046","article-title":"Emerging nanoparticle-based strategies for advanced cancer imaging and diagnosis","volume":"683","author":"Kamyab","year":"2025","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.critrevonc.2026.105304_bib48","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.trecan.2024.01.003","article-title":"Targeting solid tumor antigens with chimeric receptors: cancer biology meets synthetic immunology","volume":"10","author":"Kembuan","year":"2024","journal-title":"Trends Cancer"},{"key":"10.1016\/j.critrevonc.2026.105304_bib49","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.trecan.2025.08.009","article-title":"Overcoming solid-tumor barriers: armored CAR-T cell therapy","volume":"11","author":"Kwon","year":"2025","journal-title":"Trends Cancer"},{"key":"10.1016\/j.critrevonc.2026.105304_bib50","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1101\/gad.856201","article-title":"The hepatitis B virus encoded oncoprotein pX amplifies TGF-\u03b2 family signaling through direct interaction with Smad4: potential mechanism of hepatitis B virus-induced liver fibrosis","volume":"15","author":"Lee","year":"2001","journal-title":"Genes Dev."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105304_bib51","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41575-021-00508-3","article-title":"Cancer stem cells in hepatocellular carcinoma \u2014 from origin to clinical implications","volume":"19","author":"Lee","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.critrevonc.2026.105304_bib52","article-title":"Targeting hepatocellular carcinoma heterogeneity with FAP and GPC3-specific tandem CAR-T cells","volume":"32","author":"Li","year":"2024","journal-title":"Mol. Ther. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105304_bib53","article-title":"Targeting hepatocellular carcinoma heterogeneity with FAP and GPC3-specific tandem CAR-T cells","volume":"32","author":"Li","year":"2024","journal-title":"Mol. Ther. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105304_bib54","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ajg.2024.12.002","article-title":"Chimeric antigen receptor-T cells targeting AFP-GPC3 mediate increased antitumor efficacy in hepatocellular carcinoma","volume":"26","author":"Li","year":"2025","journal-title":"Arab J. Gastroenterol."},{"key":"10.1016\/j.critrevonc.2026.105304_bib55","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.1016\/j.ymthe.2024.07.020","article-title":"Armored bicistronic CAR T cells with dominant-negative TGF-\u03b2 receptor II to overcome resistance in glioblastoma","volume":"32","author":"Li","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.critrevonc.2026.105304_bib56","first-page":"727","article-title":"Clinical technology advances driving in vivo CAR therapy","volume":"23","author":"Li","year":"2025","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.critrevonc.2026.105304_bib57","doi-asserted-by":"crossref","DOI":"10.21037\/tgh-24-41","article-title":"Hepatocellular carcinoma risk prediction and early detection in patients with metabolic dysfunction associated steatotic liver disease","volume":"9","author":"Liang","year":"2024","journal-title":"Transl. Gastroenterol. Hepatol."},{"key":"10.1016\/j.critrevonc.2026.105304_bib58","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.62347\/VPYE3817","article-title":"Inactivation of ERK1\/2 in cancer-associated hepatic stellate cells suppresses cancer-stromal interaction by regulating extracellular matrix in fibrosis","volume":"14","author":"Lin","year":"2024","journal-title":"Am. J. Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105304_bib59","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1186\/s12967-024-05724-4","article-title":"Radiotherapy enhances the anti-tumor effect of CAR-NK cells for hepatocellular carcinoma","volume":"22","author":"Lin","year":"2024","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.critrevonc.2026.105304_bib60","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1158\/1078-0432.CCR-16-1203","article-title":"Targeting alpha-fetoprotein (AFP)-MHC complex with CART-cell therapy for liver cancer","volume":"23","author":"Liu","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105304_bib61","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s12672-025-02095-0","article-title":"Biological roles and clinical applications of EpCAM in HCC","volume":"16","author":"Liu","year":"2025","journal-title":"Discov. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105304_bib62","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41571-021-00573-2","article-title":"Immunotherapies for hepatocellular carcinoma","volume":"19","author":"Llovet","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105304_bib63","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s12672-026-04473-8","article-title":"Obstacles and improvement strategies for CAR-T cell therapy in solid tumors","volume":"17","author":"Luo","year":"2026","journal-title":"Discov. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105304_bib64","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s40164-023-00393-3","article-title":"ASAP2 interrupts c-MET-CIN85 interaction to sustain HGF\/c-MET-induced malignant potentials in hepatocellular carcinoma","volume":"12","author":"Ma","year":"2023","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105304_bib65","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-023-01723-z","article-title":"CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances","volume":"22","author":"Maalej","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105304_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.120572","article-title":"Tumor-associated macrophages: potential target of natural compounds for management of breast cancer","volume":"301","author":"Malla","year":"2022","journal-title":"Life Sci."},{"key":"10.1016\/j.critrevonc.2026.105304_bib67","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1177\/1352458512438455","article-title":"Increased expression of ER stress- and hypoxia-associated molecules in grey matter lesions in multiple sclerosis","volume":"18","author":"McMahon","year":"2012","journal-title":"Mult. Scler. J."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105304_bib68","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s12282-021-01231-2","article-title":"Prognostic significance and targeting tumor-associated macrophages in cancer: new insights and future perspectives","volume":"28","author":"Mehraj","year":"2021","journal-title":"Breast Cancer"},{"key":"10.1016\/j.critrevonc.2026.105304_bib69","article-title":"Dielectrophoresis-based microfluidics for detection and separation of circulating tumor cells","volume":"9","author":"Najafipour","year":"2025","journal-title":"Sens. Actuators Rep."},{"key":"10.1016\/j.critrevonc.2026.105304_bib70","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1483834","article-title":"The complex role of immune cells in antigen presentation and regulation of T-cell responses in hepatocellular carcinoma: progress, challenges, and future directions","volume":"15","author":"Ning","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105304_bib71","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1490911","article-title":"Logic-gated and contextual control of immunotherapy for solid tumors: contrasting multi-specific T cell engagers and CAR-T cell therapies","volume":"15","author":"Nolan-Stevaux","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105304_bib72","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.hbpd.2024.09.003","article-title":"Fibrotic liver extracellular matrix induces cancerous phenotype in biomimetic micro-tissues of hepatocellular carcinoma model","volume":"24","author":"Nouri","year":"2025","journal-title":"Hepatobiliary Pancreat. Dis. Int."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105304_bib73","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1038\/s41417-024-00844-x","article-title":"AAV-mediated combination gene therapy of inducible Caspase 9 and miR-199a-5p is therapeutic in hepatocellular carcinoma","volume":"31","author":"Pathak","year":"2024","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.critrevonc.2026.105304_bib74","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2147\/IJN.S441135","article-title":"TME-related biomimetic strategies against cancer","volume":"19","author":"Peng","year":"2024","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.critrevonc.2026.105304_bib75","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3390\/cancers16193339","article-title":"Advancement and challenges in monitoring of CAR-T cell therapy: a comprehensive review of parameters and markers in hematological malignancies","volume":"16","author":"Ploch","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105304_bib76","doi-asserted-by":"crossref","DOI":"10.1093\/jimmun\/vkaf283.1757","article-title":"Measurement of human immune cells producing the immunosuppressive\/cell repair cytokines TGF-b, IL-10 and others achieved using a novel 50-parameter CyTOF intracellular cytokine staining panel 4022","volume":"214","author":"Polanco","year":"2025","journal-title":"J. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105304_bib77","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jhepr.2019.05.001","article-title":"The oncogenic role of hepatitis delta virus in hepatocellular carcinoma","volume":"1","author":"Puigveh\u00ed","year":"2019","journal-title":"JHEP Rep."},{"key":"10.1016\/j.critrevonc.2026.105304_bib78","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens12101220","article-title":"Prevalence of hepatocellular carcinoma in hepatitis B population within Southeast Asia: a systematic review and meta-analysis of 39,050 participants","volume":"12","author":"Rabaan","year":"2023","journal-title":"Pathogens"},{"issue":"17","key":"10.1016\/j.critrevonc.2026.105304_bib79","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17172898","article-title":"Advancing CAR T-cell therapy in solid tumors: current landscape and future directions","volume":"17","author":"Rafii","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105304_bib80","article-title":"The extracellular matrix in hepatocellular carcinoma: mechanisms and therapeutic vulnerability","volume":"4","author":"Roy","year":"2023","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.critrevonc.2026.105304_bib81","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.jcyt.2024.03.484","article-title":"Synthetic biology approaches for enhancing safety and specificity of CAR-T cell therapies for solid cancers","volume":"26","author":"Russell","year":"2024","journal-title":"Cytotherapy"},{"key":"10.1016\/j.critrevonc.2026.105304_bib82","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3390\/ijms23073778","article-title":"Tumor microenvironment of hepatocellular carcinoma: challenges and opportunities for new treatment options","volume":"23","author":"Sas","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105304_bib83","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/neup.12235","article-title":"TMEM119 marks a subset of microglia in the human brain","volume":"36","author":"Satoh","year":"2016","journal-title":"Neuropathology"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105304_bib84","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s43066-023-00263-x","article-title":"Targeting liver cancer stem cell through EpCAM therapy targeted with chemotherapy endorse enhanced progression in hepatocellular carcinoma","volume":"13","author":"Sekar","year":"2023","journal-title":"Egypt. Liver J."},{"key":"10.1016\/j.critrevonc.2026.105304_bib85","doi-asserted-by":"crossref","DOI":"10.3389\/frtra.2023.1238535","article-title":"Promises and challenges of a decentralized CAR T-cell manufacturing model","volume":"2","author":"Shah","year":"2023","journal-title":"Front. Transplant."},{"key":"10.1016\/j.critrevonc.2026.105304_bib86","doi-asserted-by":"crossref","first-page":"533","DOI":"10.3390\/cancers15020533","article-title":"Hepatitis virus and hepatocellular carcinoma: recent advances","volume":"15","author":"Shen","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105304_bib87","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1557157","article-title":"Allogeneic CART progress: platforms, current progress and limitations","volume":"16","author":"Shokati","year":"2025","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105304_bib88","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105304_bib89","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1038\/s41401-024-01287-8","article-title":"GPC3-targeted CAR-T cells expressing GLUT1 or AGK exhibit enhanced antitumor activity against hepatocellular carcinoma","volume":"45","author":"Sun","year":"2024","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.critrevonc.2026.105304_bib90","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.70069","article-title":"Cytokine release syndrome in solid tumors","volume":"131","author":"Synnott","year":"2025","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2026.105304_bib91","doi-asserted-by":"crossref","DOI":"10.1159\/000542438","article-title":"CAR-T cell therapy for solid tumors","author":"Tony","year":"2025","journal-title":"Transfus. Med. Hemotherapy 52 96108"},{"key":"10.1016\/j.critrevonc.2026.105304_bib92","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/978-981-95-3628-3_10","article-title":"Next-generation CARs and beyond: synthetic biology and logic-gates in next-generation CARs","author":"Umadevi","year":"2026","journal-title":"Adv. CAR T-Cell Ther. Tumors"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105304_bib93","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/s41587-024-02446-2","article-title":"Beyond the blood: expanding CAR T cell therapy to solid tumors","volume":"43","author":"Uslu","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.critrevonc.2026.105304_bib94","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1056\/NEJMra1713263","article-title":"Hepatocellular Carcinoma","volume":"380","author":"Villanueva","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105304_bib95","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2021.108784","article-title":"Interleukin 4 promotes anti-inflammatory macrophages that clear cartilage debris and inhibits osteoclast development to protect against osteoarthritis","volume":"229","author":"von Kaeppler","year":"2021","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105304_bib96","article-title":"332\u2005A CD70 armored glypican-3 (GPC3) CAR-T therapy for treating advanced hepatocellular carcinoma","volume":"12","author":"Wang","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105304_bib97","doi-asserted-by":"crossref","unstructured":"Wang, J., Cao, W., Huang, J., Zhou, Y., Zheng, R., Lou, Y., Yang, J., Tang, J., Ye, M., Hong, Z., Wu, J., Ding, H., Zhang, Y., Sheng, J., Lu, Xinjiang, Xu, P., Lu, Xiongbin, Bai, X., Liang, T., Zhang, Q., 2025. Tumor-associated CD19$^+$ macrophages induce immunosuppressive microenvironment in hepatocellular carcinoma.","DOI":"10.1038\/s41467-026-69638-z"},{"key":"10.1016\/j.critrevonc.2026.105304_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.216038","article-title":"Immune checkpoint inhibitor resistance in hepatocellular carcinoma","volume":"555","author":"Wang","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.critrevonc.2026.105304_bib99","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11033-025-11263-y","article-title":"Anti-tumor effects of GPC3 CAR-iNKT cells in murine models of hepatocellular carcinoma","volume":"53","author":"Wang","year":"2026","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.critrevonc.2026.105304_bib100","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3390\/ijms241512317","article-title":"CRISPR\/Cas9: a powerful strategy to improve CAR-T cell persistence","volume":"24","author":"Wei","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105304_bib101","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/imm.13677","article-title":"Application of adoptive cell therapy in hepatocellular carcinoma","volume":"170","author":"Wu","year":"2023","journal-title":"Immunology"},{"key":"10.1016\/j.critrevonc.2026.105304_bib102","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.tibtech.2023.08.005","article-title":"Chimeric antigen receptor therapy meets mRNA technology","volume":"42","author":"Wu","year":"2024","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.critrevonc.2026.105304_bib103","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1124\/mol.116.107706","article-title":"Advances in hypoxia-mediated mechanisms in hepatocellular carcinoma","volume":"92","author":"Xiong","year":"2017","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.critrevonc.2026.105304_bib104","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1007690","article-title":"Hepatitis be antigen induces the expansion of monocytic myeloid-derived suppressor cells to dampen T-cell function in chronic hepatitis B virus infection","volume":"15","author":"Yang","year":"2019","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.critrevonc.2026.105304_bib105","article-title":"Safety and efficacy of JWATM204, a novel glypican-3 (GPC3)-targeted CAR T cell therapy for advanced hepatocellular carcinoma: a phase I dose-escalation study","author":"Yang","year":"2025","journal-title":"Cancer Pathog. Ther."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105304_bib106","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/s41423-023-01123-9","article-title":"Inactivation of TGF-\u03b2 signaling in CAR-T cells","volume":"21","author":"Yang","year":"2024","journal-title":"Cell. Mol. Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105304_bib107","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s10555-024-10232-4","article-title":"Correlative studies reveal factors contributing to successful CAR-T cell therapies in cancer","volume":"44","author":"Yao","year":"2024","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.critrevonc.2026.105304_bib108","first-page":"223","article-title":"Combined assessment of TGF-beta-1 and alpha-fetoprotein values improves specificity in the diagnosis of hepatocellular carcinoma and other chronic liver diseases in Malaysia","volume":"64","author":"Yasmin Anum","year":"2009","journal-title":"Med. J. Malays."},{"key":"10.1016\/j.critrevonc.2026.105304_bib109","doi-asserted-by":"crossref","first-page":"6227","DOI":"10.7314\/APJCP.2013.14.11.6227","article-title":"Viral hepatitis and liver cancer in Korea: an epidemiological perspective","volume":"14","author":"Yeo","year":"2013","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/j.critrevonc.2026.105304_bib110","doi-asserted-by":"crossref","first-page":"3405","DOI":"10.1038\/sj.onc.1211000","article-title":"Hepatitis B virus X protein induces the expression of MTA1 and HDAC1, which enhances hypoxia signaling in hepatocellular carcinoma cells","volume":"27","author":"Yoo","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2026.105304_bib111","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jhep.2022.01.026","article-title":"PARG inhibition limits HCC progression and potentiates the efficacy of immune checkpoint therapy","volume":"77","author":"Yu","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.critrevonc.2026.105304_bib112","first-page":"275","article-title":"CAR NK cell therapy for solid tumors: potential and challenges","volume":"8","author":"Yu","year":"2025","journal-title":"Antib. Ther."},{"key":"10.1016\/j.critrevonc.2026.105304_bib113","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.2147\/JHC.S347932","article-title":"Safety and efficacy of atezolizumab and bevacizumab combination as a first line treatment of advanced hepatocellular carcinoma","volume":"10","author":"Zanuso","year":"2023","journal-title":"J. Hepatocell. Carcinoma"},{"key":"10.1016\/j.critrevonc.2026.105304_bib114","doi-asserted-by":"crossref","DOI":"10.1016\/j.polymdegradstab.2023.110348","article-title":"Flame retardant properties of Viscose\/Carrageenan fibers blend papers","volume":"212","author":"Zhai","year":"2023","journal-title":"Polym. Degrad. Stab."},{"key":"10.1016\/j.critrevonc.2026.105304_bib115","doi-asserted-by":"crossref","first-page":"8951","DOI":"10.2147\/CMAR.S252679","article-title":"Circrna CDR1as\/miR-1287\/Raf1 axis modulates hepatocellular carcinoma progression through MEK\/ERK pathway","volume":"12","author":"Zhang","year":"2020","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.critrevonc.2026.105304_bib116","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.3748\/wjg.v28.i27.3346","article-title":"Regulatory T cells and their associated factors in hepatocellular carcinoma development and therapy","volume":"28","author":"Zhang","year":"2022","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.critrevonc.2026.105304_bib117","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.ymthe.2024.12.014","article-title":"Potentiating CAR-T cell function in the immunosuppressive tumor microenvironment by inverting the TGF-\u03b2 signal","volume":"33","author":"Zheng","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.critrevonc.2026.105304_bib118","doi-asserted-by":"crossref","first-page":"500","DOI":"10.5009\/gnl20223","article-title":"Tumor-associated macrophages in hepatocellular carcinoma: friend or foe?","volume":"15","author":"Zhou","year":"2020","journal-title":"Gut Liver"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105304_bib119","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s12672-023-00681-8","article-title":"The role of myeloid-derived suppressor cells in liver cancer","volume":"14","author":"Zhou","year":"2023","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105304_bib120","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1489649","article-title":"CAR-T cell therapy for hepatocellular carcinoma: current trends and challenges","volume":"15","author":"Zhou","year":"2024","journal-title":"Front. Immunol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826001915?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826001915?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T06:40:44Z","timestamp":1778481644000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826001915"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":120,"alternative-id":["S1040842826001915"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105304","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Engineering CAR-based cellular immunotherapy for hepatocellular carcinoma: Current barriers, innovative strategies, and future directions","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105304","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105304"}}